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Background: This study was designed to establish a biomarker risk model for predicting bone metastasis in stage III
non-small cell lung cancer (NSCLC).
Methods: The model consists of 105 cases of stage III NSCLC, who were treated and followed up. The patients
were divided into bone metastasis group (n = 45) and non-bone metastasis group (other visceral metastasis and
those without recurrence) (n = 60). Tissue microarrays were constructed for immunohistochemical study of 10
molecular markers associated with bone metastasis, based on which a model was established via logistic regression
analysis for predicting the risk of bone metastases. The model was prospectively validated in another 40 patients
with stage III NSCLC.
Results: The molecular model for predicting bone metastasis was logit (P) =− 2.538 + 2.808 CXCR4 +1.629 BSP
+0.846 OPN-2.939 BMP4. ROC test showed that when P≥ 0.408, the sensitivity was up to 71% and specificity of 70%.
Model validation in the 40 cases in clinical trial (NCT 01124253) demonstrated that the prediction sensitivity of the
model was 85.7%, specificity 66.7%, Kappa: 0.618, with a high degree of consistency.
Conclusion: The molecular model combining CXCR4, BSP, OPN and BMP4 could help predict the risk of bone
metastasis in stage IIIa and IIIb resected NSCLC.
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Tumor cells homing to form bone metastases is common
in non-small cell lung cancer (NSCLC), just like what is
seen in breast, prostate and thyroid cancers. Some patients
may experience bone metastasis many years after surgery
of the primary tumor. The high morbidity and significantly
increased risk of fractures associated with bone metastasis
seriously affect patients' quality of life. About 36% of all
lung cancers and and 54.5% of stage II-IIIA NSCLC
showed postoperative recurrence or metastasis [1]. Many
lung cancer patients expect new and more sensitive* Correspondence: zzhou1116@hotmail.com
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reproduction in any medium, provided the ormarkers to predict metastatic diseases. If bone metastasis
can be predicted early enough, then effective prevention
could be started and may result in an improvement in sur-
vival [2]. The molecular and cellular mechanisms leading
to the development of bone metastasis in NSCLC remain
unclear, therefore in this study, we investigated the current
understanding of bone metastasis in NSCLC. We con-
structed tissue microarray, and used immunohistochemical
method to assess the expression of 10 bone metastasis-
related tumor markers in primary NSCLC tissue, which
involved multi-step process of bone metastasis [3], includ-
ing the proliferation, adhesion, escape (MMPs, OPN, c-
Src) of primary tumors; targeted metastasis to bone
(CXCR4); bone-specific adhesion and implantation (BSP);
formation of metastases in bone (IGF1R, BMPs, PTHrP)
and metastasis-associated cell signaling pathways (PI3K,
NFκB). We established a molecular model composed of
biological markers to predict the risk of bone metastasis intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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risk of bone metastasis for early intervention.
Patients and methods
Patients
The patients for establishing the model were 105 cases of
pathologically-confirmed stage III NSCLC, who were the
whole cohort and treated by complete resection from June
2002 to December 2006 at Shanghai Chest Hospital, and
were followed up until December 2008. Before surgery,
these patients did not have any chemo/radiotherapy, im-
munotherapy or other treatments that could significantly
modulate the cancer cell biology. All the patients had
complete resection of the tumor and staged accoding
UICC 1999. The patients included 65 males and 40
females. The median age was 59 (34 to 76) years. Patho-
logical examination showed 88 cases of adenocarcinoma,
and 17 cases of non-adenocarcinoma. Stage IIIa was con-
firmed in 86 cases, and IIIb in 19 cases. Cisplatin-based ad-
juvant chemotherapy was administrated to patient with
completely resected NSCLC. Three or more cycles of post-
operative adjuvant chemotherapy were received in 76
cases. The 45 cases of bone metastasis were designated as
bone metastasis group. The remaining 60 cases with vis-
ceral metastasis or without metastasis were defined as
non-bone metastasis group.
The patients recruited in the validation group in the pro-
spective model consists of 40 cases of pathologically-con-
firmed Stage III NSCLC the whole cohort enrolled in
clinical trial (NCT 01124253), who had received complete
surgical resection from July 2007 to August 2009, 26 males
and 14 females. The median age was 57 (41 to 76) years.
Pathological examination showed 33 cases of adenocarcin-
oma, and 7 cases of non-adenocarcinoma. Stage IIIa was
confirmed in 35 cases, and IIIb in 5 cases.
Preparation of tissue microarray
HE sections were examined under a microscope to iden-
tify and mark the cancer nests. HE sections were used to
mark the corresponding sampling site on paraffin blocks
of the donor. Preparation of tissue chip block: The or-
dinary pathological paraffin was melted and precipitated
repeatedly for 3 times. Then 3% refined beeswax was
added to prepare blank paraffin blocks of 32 mm×15
mm×10 mm, which were cooled at room temperature.
Design and preparation of tissue microarray: an 8 × 5 tis-
sue array was designed and made into module with the
drilling system. A punch needle with a diameter of 2 mm
was used to remove the tissue cores one by one from the
specified site of donor paraffin blocks. The tissue cores
were put into a pre-designed array module, arranged as
tissue microarray. The prepared tissue microarrays were
placed in an instrument at 60°C for 20 min. The modules
were pressed slightly to make the tissue cores level andalign in the module. The prepared module was then cut
into conventional 2 μm slice and mounted on a silica
slide. The slide was incubated overnight at 60°C. Each
chip of the tissue microarray contained the 20 tissue
samples and 2 normal controls. Each case repeated.
Immunohistochemistry S-P assay
Mouse anti-human monoclonal antibodies against parathy-
roid hormone related protein (PTHrP), osteopontin (OPN),
Src proto-oncogene (c-Src), matrix metalloproteinase - 2
(MMP2), chemokine receptor type 4 (CXCR4), phosphati-
dylinositol kinase (PI3K), bone sialoprotein (BSP), nuclear
transcription factor (NFκB), insulin-like growth factor-IR
(IGF-1R), bone morphogenetic protein −4 (BMP-4) were
purchased from Beijing Boao Sen Biotechnology Co., Ltd.
SP kit was purchased from Fuzhou Maixin Biotechnology
Development Co., Ltd. Antigen retrieval was conducted
according to the protocol. The known positive tissue sec-
tions of lung cancer were used as positive control, PBS in-
stead of primary antibody as negative control. Evaluation
criteria: immunostaining score was calculated based on the
sum of the percent positivity of stained tumour cells and
the staining intensity. The percent positivity was scored as
“0” (<5%, negative), “1” (5–25%, sporadic), “2” (25–50%,
focal), “3” (>50%, diffuse). The staining intensity was scored
as “0” (no staining), “1” (weakly stained), “2” (moderately
stained), and “3” (strongly stained). Both percent positivity
of cells and staining intensity were decided under double-
blind condition. The final expression score was calculated
with the value of percent positivity score× staining intensity
score, which ranged from 0 to 9. We defined expression
level as follow: “”0 (score 0–1), “+” (score 2–3), “++” (score
4–6) and “+++” (score> 6) [4]. Expression (++) or more be
considered positive.
Follow-up and database construction
All patients were followed-up regularly by a designated
staff, who collected all the information to a central data-
base. Generally, we followed up the patients 3 to 4 times
a year in the first 2 years, and once in half a year in the
following 3 years. The disease control time (DCT) was
defined as the time interval from surgical section to the
recurrence. The last follow-up visit was on June 30,
2008. The DCT and site of recurrence were followed-up
in the same way in validation group, for whom the date
of last follow-up was June 30, 2011.
Statistical analysis
SPSS 17.0 software was used for data analysis. Categorical
data were described by percentage to test group differ-
ences. Logistic regression analysis was applied to estimate
the parameters using maximum likelihood estimation
method, α=0.05, for establishing a model to predict the
risk of bone metastasis in resected stage III NSCLC. Model
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model was also tested by receiver operating characteristics
(ROC) analysis, and prospectively validated with kappa
test. P <0.05 was considered statistically significant.Results
Model group
A total of 105 cases of stage III NSCLC patients were
analyzed, including 45 cases with bone metastasis, and
60 cases without bone metastasis. Only pathologic stage
statistically significant difference was found between
bone metastasis group and non-bone metastasis group in
terms of clinical and pathological factors (Table 1).Establishment of the prediction model of bone metastasis
A number of cancer molecular markers associated with
bone metastasis were assessed by immunohistochemical
technique, including PTHrP, OPN, c-Src, MMP2, CXCR4,
PI3K, BSP, NFκB, IGF-1R, and BMP4. Immunohistochemi-
cally, PTHrP, OPN, c-Src, MMP2, CXCR4, BSP, NFκB, IGF
-1R, and BMP4 were mainly expressed in cytoplasm. PI3K
was mainly expressed in cytoplasm, partly in the nucleus;
BMP4expressed slight weakly (Figure 1). Chi-square ( 2) test
showed that OPN, CXCR4, BSP, BMP4 were associated
with bone metastasis (Table 2). A prediction model was
established via Logistic regression analysis: logit (P)=−
2.538 +2.808 CXCR4 +1.629 BSP +0.846 OPN-2.939 BMP4.
Hosmer and Lemeshow test p=0.065. ROC test (Figure 2)
suggested that the area under the curve was 81.5% (P:
0.041, 95% CI 73.4% to 89.5%). When P=0.408, the sensi-
tivity was up to 71%, specificity 70%. Namely, P≥ 0.408 can
be used as the screening indicator in this model to identifyTable 1 Comparison of major clinico-pathological factors betw














No 15 (33.3)those at high risk of bone metastasis in resected stage III
NSCLC.
Prospective validation of bone metastasis prediction
model
A total of 40 cases of stage III NSCLC were enrolled
from July 2007 to August 2009. TMA was constructed in
Dec.2010 and assessed for OPN, CXCR4, BSP and
BMP4. According to this model, we predicted 8 cases
would have bone metastasis and 32 cases would not.
Bone metastasis was identified in 7 (17.5%) cases. Other
visceral metastasis was found in 20 (50%) cases. No me-
tastasis was identified in 13 (32.5%) cases. The prediction
sensitivity of the model was 85.7%, specificity of 66.7%,
Kappa: 0.618, with a high degree of consistency.
Discussion
Bone metastases are classified as osteolylic, osteoselerotic
or mixed lesions. Several molecular mechanism bring
about cancer cell to metastasis to bone, and osteotropric
cancer cells are believed to acquire bone cell-like proper-
ties which improve homing, adhesion, proliferation and
survival in the bone microenvironment [2].
We used tissue microarray technology in this study. It
is a good solution to a large volume of tumor marker
tests and the comparability of results. Immunohisto-
chemical assay was used to detect the expression of 10
molecular markers in 105 patients completely resected
stage III with NSCLC tissue from the 2002 to 2006 the
whole cohort. These molecular markers included PTHrP,
OPN, c-Src, MMP2, CXCR4, PI3K, BSP, NFκB, IGF-1R,
and BMP4. All these molecules may, individually, play
important roles in breast cancer or prostate cancer bone
metastasis. However, to our knowledge, there have beeneen NSCLC patients with or without bone metastasis











Figure 1 (a) Expression positive (++) of biomarkers of OPN, c-Src,
MMP2, CXCR4, BSP, PTHP, IGF-1R, BMP4, PI3K and NK-kappaB
(original magnification Χ100), (b) Expression of biomarkers of
OPN, CXCR4, BMP4, BSP (original magnification Χ200).
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and make weighted examinations of them, so as to con-
struct a panel of makers for the prediction of NSCLC
bone metastasis. Bearing this in mind, we designed this
study in order to early predict the bone metastasis for
more personalized targeted therapy.
Univariate analysis found that high expression of OPN,
CXCR4, and BSP and low expression of BMP4 had sig-
nificantly impact on bone metastasis in resected Stage III
NSCLC. OPN was dominantly presented in bone matrix.
It interacts with its receptor integrin vβ3 to promote cell
proliferation, invasion and adhesion. Fong et al. [5] found
that OPN could increase the metastasis ability of lung
cancer cells through activation of integrin/FAK/AKT and
NF-κB signaling pathway. In addition, OPN also
increases the activity of EGFR tyrosine kinase, and Met
kinase to promote tumor cell migration by inducing
EGFR and HGFR (Met) expression. OPN may down-
regulate the expression of Syndecan-1 to reduce the ad-
hesion between tumor cells, and thereby encouraging
tumor metastasis [6,7]. Study in metastatic breast cancer
revealed [3] that the breast cancer cells high expression
of CXCR4 metastasized to the corresponding target
organs with high expression of CXCL12, such as lymphTable 2 Correlation between cancer biomarkers and bone
metastasis
Biomarkers Bone metastasis Non-bone metastasis P
valuen (%) n (%)
OPN + 40 (93.0) 48 (77.4) 0.033
- 3 (7.0) 14 (22.6)
c-Src + 45 (100) 56 (93.3) 0.133
- 0 (0) 4 (6.7)
MMP2 + 38 (88.4) 47 (75.8) 0.107
- 5 (11.6) 15 (24.2)
CXCR4 + 40 (90.9) 32 (52.5) 0.000
- 4 (9.1) 29 (47.5)
BSP + 44 (97.8) 49 (81.7) 0.012
- 1 (2.2) 11 (18.3)
PTHrP + 42 (68.8) 28 (63.4) 0.647
- 19 (31.2) 16 (36.6)
IGF-1R + 58 (95.1) 39 (88.6) 0.383
- 3 (4.9) 5 (21.4)
BMP4 + 22 (48.9) 51 (85) 0.000
- 23 (51.1) 9 (15.0)
PI3K + 43 (95.6) 55 (91.7) 0.696
- 2 (4.4) 5 (8.3)
NFκB + 58 (95.1) 39 (88.6) 0.383
- 3 (4.9) 5 (21.4)
Figure 2 ROC curve of the biomarker model for predicting
bone metastasis in resected stage III non-small cell lung cancer.
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to promote tumor cell proliferation, induce the expres-
sion of MMP2, and increase invasion and metastasis.
High expression of CXCR4 not only enhances distant
metastasis, but also leads to more pronounced bone me-
tastasis relative to visceral metastasis. In vitro experi-
ments also confirmed that the high expression of CXCR4
alone was significantly associated with higher rate of
bone metastasis [8]. No significant difference was found
between bone metastasis group and non-bone metastasis
group in this study, although MMP2 was over expressed
in the patients with distant metastasis. According to the
"seed and soil" theory, some tumor cells prefer to bone
metastases due to their inherent biological characteris-
tics, BSP and c-Src for example. BSP has cell adhesion
function, and is involved in cell migration and signal rec-
ognition [9]. BSP acts as the ligand of integrin in osteo-
blasts, osteoclasts, and tumor cells of bone metastasis. It
binds with integrin and play a role in osteocyte differen-
tiation, bone matrix mineralization, as well as adhesion,
proliferation and metastasis of tumor cells [10,11]. In the
distant metastasis of both breast cancer and prostate
cancer, the incidence of bone metastasis is higher than
that of visceral metastasis in case of high expression of
BSP. The level of BSP expression in the cancer cells of
bone metastasis is higher than that in the primary tumor.
The primary tumor with high expression of BSP may be
more inclined to bone as a target organ of metastasis.
And the microenvironment of bone further up-regulates
the expression of the BSP, while the microenvironmentof visceral organs reduces the expression of BSP. Positive
expression of BSP in tumor cells suggests that BSP has
contributed to bone metastasis [12]. Studies comparing
bone and visceral metastasis in breast cancer indicated
that up-regulation of c-Src gene can increase bone me-
tastasis, while down-regulation of this gene will decrease
the malignant phenotype of breast cancer cells, and re-
duce bone metastasis [13]. However, high expression of
c-Src was not associated with stronger bone metastasis
than other distant metastasis in this study. BMPs are
bone morphogenetic proteins, which is a member of
growth factor family. Functional studies have shown that
BMPs are involved in both promotion and inhibition of
tumor cell growth [14]. BMPs secreted by tumor cells
can induce cell differentiation of osteoblasts, increase the
formation of new bone and promote bone
mineralization. Recent evidence suggests [15] that the
BMP4-induced phenotypic changes were mediated
through the activation of the canonical SMAD signaling
pathway. It has been reported that BMP4 is overex-
pressed in melanoma cell line and lung cancer. BMP4
plays an important role in bone metastasis of prostate
cancer [16], and BMP4 overexpression inhibits prolifera-
tion and induces apoptosis in many cancer cell line
[15,17]. This study also showed that BMP-4 expression
was lower in primary tumors. Bone metastasis of lung
cancer is a dynamic process involving bone resorption
resulted from tumor cell-induced osteolysis and bone
formation due to osteoblasts. This study didn’t show
PTHrP and IGF-1R overexpression in NSCLC tissue
related NSCLC bone metastasis. PTHrP is required for
colony of bone metastasis of cancer cells. It is a cytokine
produced by the metastatic cancer cells [18]. But Hen-
derson [19] had demonstrated that bone metastases that
do not express PTHrP in primary breast cancer begin to
do so when they reach bone. The bone microenviron-
ment seems to provide what is needed for the breast
cancer cells to produce PTHrP, even if they could not
produce it before they got there. This study demon-
strated that PTHrP was expressed only in 66.67% of the
primary tumors. Breast cancer overexpress IGF-1R
through promoting proliferation and reducing apoptosis
to increase bone metastasis [20], the effects of IGF-1R
have been confirmed in bone metastasis of prostate can-
cer [21] but the role of IGF-1R overexpress in NSCLC
bone metastasis is not clear, it still needs to be further
investigated.
Multivariate Logistic regression has successfully estab-
lished a model for predicting the risk of bone metastasis
in resected Stage III NSCLC: logit (P) =− 2.538 +2.808
CXCR4 +1.629 BSP +0.846 OPG-2.939BMP4. The area
under the ROC curve was 81.5%. When P= 0.408, the
sensitivity was up to 71%, specificity 70%. The model has
successfully validated in 40 patients with resected stage
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trial, who were followed up for 3 years. The model
showed a sensitivity of 85.7% and specificity of 66.7%,
Kappa: 0.618. The results are highly consistent. The
model based on bone metastasis-associated biomarkers
established in this study is useful in providing rationale
for the screening, intervention and targeted therapy of
bone metastasis in lung cancer.
Although the results are interesting, the limitations of
this study should be acknowledged. The patients enrolled
into the prediction model and validation model were
whole cohort of completed resected stage III patients,
not including patients from other groups. Therefore,
there might be selection bias in the model construction
and results interpretation. The results might be more
suitable to clinically stage III patients. Any generalization
to other stages should not be expected. In the future, a
bigger study with larger sample size with different stages,
could help more objectively judge the value of this pre-
diction model.
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